Evidence map›Paper›PMID 41063661›Full record

Trial reportThe Journal of infectious diseases2026

Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis.

Fredericka Albertina Sesay, Kevin Oware, Lauren R Violette, Deborah Donnell, Josephine B Odoyo, Victor Omollo, Felix O Mogaka, R Scott McClelland, Jennifer E Balkus, Elizabeth A Bukusi and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fredericka Albertina SesayDepartments of Epidemiology, University of Washington, Seattle, WA, USA.
Kevin OwareCentre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Lauren R VioletteMedicine (Infectious Diseases), University of Washington, Seattle, WA, USA.ORCID 0000-0001-6469-7298
Deborah DonnellFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-0587-7480
Josephine B OdoyoCentre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.ORCID 0000-0003-1749-8645
Victor OmolloCentre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.ORCID 0000-0002-3457-4876
Felix O MogakaCentre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.ORCID 0000-0002-7750-0404
R Scott McClellandDepartments of Epidemiology, University of Washington, Seattle, WA, USA.ORCID 0000-0003-2574-4201
Jennifer E BalkusDepartments of Epidemiology, University of Washington, Seattle, WA, USA.ORCID 0000-0003-2015-4739
Elizabeth A BukusiCentre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.ORCID 0000-0002-2031-2808
Jared M BaetenDepartments of Epidemiology, University of Washington, Seattle, WA, USA.ORCID 0000-0001-8242-8438
Jenell StewartHennepin Healthcare Research Institute, Minneapolis, MN, USA.ORCID 0000-0002-8587-1096

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
PrEP and dPEP: Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxisR01AI145971 · NIAID · UNIVERSITY OF WASHINGTON · PI BAETEN, JARED, BUKUSI, ELIZABETH ANNE · 2019 to 2023
$4.0M
Understanding STI and HIV prevention adherence among Kenyan womenK23MH124466 · NIMH · UNIVERSITY OF WASHINGTON · PI STEWART, JENELL · 2020 to 2024
$939k
NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI145971NIH HHS K23MH124466NIH HHS P30AI027757NIH HHS R01AI145971NIMH NIH HHS K23 MH124466
6 · The paper itself

Abstract

Doxycycline treats and prevents several bacterial and parasitic infections and has been proposed as a possible treatment for Trichomonas vaginalis. Nested in a trial of doxycycline postexposure prophylaxis among cisgender women in Kenya, we conducted a secondary analysis of incident T. vaginalis infections. Among 224 cisgender women randomized to doxycycline postexposure prophylaxis and 225 to standard-of-care, there were 27 T. vaginalis diagnoses in the doxycycline postexposure prophylaxis group and 29 in the standard-of-care group (RR: 0.96, 95% CI: 0.54-1.73, P = .9). Understanding doxycycline postexposure prophylaxis's impact on T. vaginalis remains an important public health question that warrants further investigation.

Indexed as

Anti-Bacterial AgentsDoxycyclinePost-Exposure ProphylaxisTrichomonas InfectionsTrichomonas vaginalisTrichomonas VaginitisAdolescentAdultFemaleHumansKenyaYoung AdultAnti-Bacterial AgentsDoxycyclinedoxycyclineDoxyPEPpreventionTrichomonas vaginaliswomen

Identifiers

PMID41063661
PMCPMC12875391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.